Riad Sherif, Oculis CEO
Can a topical treatment beat blockbuster eye injectables? A Swiss biotech has the cash now to find out
The eye disease therapy market is a lucrative one but a pain for patients who must rely on invasive injections a few times per year. A Swiss biotech is hoping to rewrite the game with a pair of lead topical drugs, and it’s got a fresh round of cash in its war chest to get there.
Oculis has bagged a $57 million Series C it will use to advance lead drug OCS-01 into late-stage trials in its bid to unseat in-the-eye injectables for eye disease as well as push ahead another candidate, OCS-02, the company said Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
